Highest-materiality recent filing
Quantum Cyber licenses drone/cyber IP from BP United for $5M cash and 20M shares
Exclusive, perpetual, worldwide license to BP United's IP (patents, trademarks, know-how) for drones and cyber applications.
Quantum Cyber increases equity distribution capacity to $100M; CFO Caragol moves to consulting role
Equity distribution agreement amended; offering amount increased from $10M to $100M.
Second closing on Apr 22, 2026: issued Series D/E preferred convertible into up to 225M ordinary shares each, representing >90% fully diluted shares.
Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance
Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.
Nasdaq notified Mainz Biomed on Mar 20, 2026 that its share price closed below $1.00 for 30 consecutive business days through Mar 19, 2026.
Quantum Cyber pre-funded $3M by David Lazar; targets acquisitions in quantum & cyber defense
David Lazar pre-funded $3M second tranche; total investment now $6M.
Mainz Biomed appoints cyber security veteran Robert Liscouski as Chairman; ticker changes to QUCY
Robert P. Liscouski appointed Chairman effective March 11, 2026; election to be ratified at April 2026 EGM.
Mainz Biomed secures $6M private placement, names David Lazar Chairman; pivots to pancreatic cancer
First tranche of $3M closed Feb 13; second $3M expected after shareholder approval by April 15, 2026.
Mainz Biomed raises $2.15M via ATM equity offering; fully utilizes prospectus supplement
Sold 1,735,194 ordinary shares at prevailing market prices for gross proceeds of $2,152,822.40.
Effective as of May 13, 2026, to fill vacancy in the composition of the Board of Directors (the “Board”), the Board of the Company appointed Peter O’Rourke to serve as a director
Max materiality 0.90 · Median 0.65 · Most common event other_material